Streptavidin偶联试剂盒- Lightning-Link® (ab102921)
概述
-
产品名称
Streptavidin偶联试剂盒- Lightning-Link® -
产品概述
Streptavidin Conjugation Kit / Streptavidin Labeling Kit ab102921 uses a simple and quick process for streptavidin labeling / conjugation of antibodies. It can also be used to conjugate other proteins or peptides. Learn about our antibody labeling kits and their advantages.
To conjugate an antibody to Streptavidin using this kit:
- add modifier to antibody and incubate for 3 hrs
- add quencher and incubate for 30 mins
The conjugated antibody can be used immediately in WB, ELISA, IHC etc. No further purification is required and 100% of the antibody is recovered for use.
Learn about buffer compatibility below; for incompatible buffers and low antibody concentrations, use our rapid antibody purification and concentration kits. Use the FAQ to learn more about the technology, or about conjugating other proteins and peptides to Streptavidin.
Custom size conjugation kits up to 100 mg are available on demand. Please contact us to discuss your requirements.
-
说明
This product is manufactured by Expedeon, an Abcam company, and was previously called Lightning-Link® Streptavidin Labeling Kit. 708-0005 is the same as the 100 µg size. 708-0010 is the same as the 3 x 100 ug size. 708-0030 is the same as the 3 x 10 ug size. 708-0015 is the same as the 1 mg size.
Amount and volume of antibody for conjugation to Streptavidin
Kit size Recommended maximum
amount of antibodyMaximum antibody
volume13 x 10 µg 3 x 10 µg 3 x 10 µL 100 µg 100 µg 100 µL 3 x 100 µg 3 x 100 µg 3 x 100 µL 1 x 1 mg 1 x 1 mg 1 x 1 mL 1 Ideal antibody concentration is 1mg/ml. 0.5 - 1 mg/ml can be used if the maximum antibody volume is not exceeded. Antibodies > 5mg/ml or < 0.5 mg/ml should be diluted /concentrated.
Buffer Requirements for Conjugation
Buffer should be pH 6.5-8.5.
Compatible buffer constituents
If a concentration is shown, then the constituent should be no more than the concentration shown. If several constituents are close to the limit of acceptable concentration, then this can inhibit conjugation.50mM / 0.6% Tris1 0.1% BSA 50% glycerol 0.1% sodium azide PBS Potassium phosphate Sodium chloride HEPES Sucrose Sodium citrate EDTA Trehalose 1 Tris buffered saline is almost always ≤ 50 mM / 0.6%
Incompatible buffer constituentsThiomerosal Proclin Glycine Arginine Glutathione DTT If a constituent of the buffer containing your antibody or protein is not listed above, please check the FAQ or contact us.
Only purified antibodies are suitable for use, ie. where other proteins, peptides, or amino acids are not present: antibodies in ascites fluid, serum or hybridoma culture are not suitable for conjugation.
Storing and handling conjugation kits
Lyophilized Lightning-Link® components are hygroscopic.
Kits are intentionally shipped at ambient temperature with silica gel to avoid exposure to moisture. Upon receipt, store the kit frozen and protect from moisture. Before opening the outer container, allow the lyophilized components to reach room temperature to minimize condensation.
性能
-
存放说明
Store at -20°C. Please refer to protocols. -
组件 1 mg 100 µg 3 x 10 µg 3 x 100 µg Modifier reagent 1 x 200µl 1 x 200µl 1 x 200µl 1 x 200µl Quencher reagent 1 x 200µl 1 x 200µl 1 x 200µl 1 x 200µl ab274136 - Streptavidin mix 1 x 1mg 1 x 100µg 3 x 10µg 3 x 100µg -
研究领域
相关产品
-
Related Products
图片
-
Conjugation - Streptavidin Conjugation Kit - Lightning-Link® (ab102921)Image from Pereira et al., Traffic, 21(5):375-385; doi: 10.1111/tra.12728. Reproduced under the Creative Commons license https://creativecommons.org/licenses/by/4.0/
Pereira, Pedro M., et al used Streptavidin Conjugation Kit - Lightning-Link® (ab102921) as part of examining super-resolution fluorescent probes for Single-molecule localization microscopy. They used the kit to conjugate Streptavidin to anti-mouse secondary antibody for use in fixed-cell imaging.
D, Pre-acquisition snapshot (WF) and SMLM reconstruction (STORM) of β-tubulin immunolabelling with B3S9L SB (B3S9L-ATTO555-BHQ2) and control probe (B3S9L-ATTO555). Scale bars are 5 µm. E, Schematic representation of the strategy used to perform β-tubulin immunolabelling (left), measurement of Full With Half Maximum (FWHM) and distances between structures on the highlighted regions in D -
Conjugation - Streptavidin Conjugation Kit - Lightning-Link® (ab102921)Image from Hoffmann et al., Sci Rep., 10(1):8869; doi: 10.1038/s41598-020-65860-x.Reproduced under the Creative Commons license https://creativecommons.org/licenses/by/4.0/Hoffmann, Ricarda M., et al used Streptavidin Conjugation Kit - Lightning-Link® (ab102921) as part of examining development of anticancer Antibody-Drug Conjugates. They used the kit to conjugate Streptavidin to Trastuzumab and trastuzumab emtansine antibodies for use in streptavidin-biotin based assay.
Investigation of cell viability upon treatment with the naked antibody (black), antibody-Streptavidin-Biotin-Saporin conjugate (orange) or Saporin alone (grey). The ribosome inhibitor Saporin, unable to enter the cell alone, can be used to investigate antibody internalization by measuring viability (MTS) of antibody-SB-Saporin conjugate-treated cells. -
Conjugation - Streptavidin Conjugation Kit - Lightning-Link® (ab102921)Image from Wang et al., Redox Biol. 24:101153; doi: 10.1016/j.redox.2019.101153. Reproduced under the Creative Commons license https://creativecommons.org/licenses/by/4.0/Wang, Xinzhi et al used Streptavidin Conjugation Kit - Lightning-Link® (ab102921) as part of examining. They used the kit to conjugate Streptavidin to recombinant proteins for use in bio-layer interferometry.
Comparison of the binding activity between PepE and TrxR1 protein (red line), PepE and TrxR1 nSec498 protein (blue line), and PepA and TrxR1 protein (black line) through BLI analysis. -
Streptavidin Conjugation KitThis illustration demonstrates a general procedure and will slightly vary dependent on the conjugate used.
数据表及文件
-
SDS download
-
Datasheet download
文献 (43)
ab102921 被引用在 43 文献中.
- Chao YY et al. Human TH17 cells engage gasdermin E pores to release IL-1α on NLRP3 inflammasome activation. Nat Immunol 24:295-308 (2023). PubMed: 36604548
- Tang Z et al. Overcoming the On-Target Toxicity in Antibody-Mediated Therapies via an Indirect Active Targeting Strategy. Adv Sci (Weinh) 10:e2206912 (2023). PubMed: 36683161
- He Z et al. BSA modification of bacterial surface: a promising anti-cancer therapeutic strategy. BMC Microbiol 23:105 (2023). PubMed: 37062822
- Park JY et al. Pancreatic Tumor-Targeting Stemsome Therapeutics. Adv Mater 35:e2300934 (2023). PubMed: 37114740
- Chen AF et al. NEAT-seq: simultaneous profiling of intra-nuclear proteins, chromatin accessibility and gene expression in single cells. Nat Methods 19:547-553 (2022). PubMed: 35501385